Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) Gross Profit (2016 - 2019)

Plus Therapeutics (PSTV) has disclosed Gross Profit for 9 consecutive years, with $589000.0 as the latest value for Q1 2019.

  • On a quarterly basis, Gross Profit rose 287.5% to $589000.0 in Q1 2019 year-over-year; TTM through Mar 2019 was $2.2 million, a 424.53% increase, with the full-year FY2018 number at $3.0 million, up 1973.97% from a year prior.
  • Gross Profit was $589000.0 for Q1 2019 at Plus Therapeutics, down from $1.4 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $1.4 million in Q4 2018 to a low of -$125000.0 in Q1 2017.
  • A 5-year average of $359764.7 and a median of $264000.0 in 2015 define the central range for Gross Profit.
  • Peak YoY movement for Gross Profit: crashed 117.7% in 2017, then surged 4483.33% in 2018.
  • Plus Therapeutics' Gross Profit stood at $765000.0 in 2015, then plummeted by 31.9% to $521000.0 in 2016, then crashed by 94.24% to $30000.0 in 2017, then soared by 4483.33% to $1.4 million in 2018, then plummeted by 57.16% to $589000.0 in 2019.
  • Per Business Quant, the three most recent readings for PSTV's Gross Profit are $589000.0 (Q1 2019), $1.4 million (Q4 2018), and $230000.0 (Q3 2018).